vs
Side-by-side financial comparison of INTELLIGENT PROTECTION MANAGEMENT CORP. (IPM) and NovaBay Pharmaceuticals, Inc. (NBY). Click either name above to swap in a different company.
INTELLIGENT PROTECTION MANAGEMENT CORP. is the larger business by last-quarter revenue ($6.1M vs $4.8M, roughly 1.3× NovaBay Pharmaceuticals, Inc.). On growth, INTELLIGENT PROTECTION MANAGEMENT CORP. posted the faster year-over-year revenue change (2091.6% vs 126.1%). Over the past eight quarters, INTELLIGENT PROTECTION MANAGEMENT CORP.'s revenue compounded faster (54.7% CAGR vs 42.5%).
Intelligent Limited is a Holding Company and Parent company headquartered in Gloucestershire, United Kingdom and was incorporated on 21 May 2008. Intelligent Limited provides a group management structure for four companies and was born out of the operations of International Intelligence Limited, a company specialising in Intelligence, Counter Espionage and TSCM sweeping.
NovaBay Pharmaceuticals, Inc. is an Emeryville, California based clinical-stage biopharmaceutical company, focused on products for eye care. Major products include Avenova, cleared by FDA for lid and lash cleansing as part of a regimen for Blepharitis. and NeutroPhase, used in treatment of Necrotizing Fasciitis
IPM vs NBY — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2024
| Metric | | |
|---|---|---|
| Revenue | $6.1M | $4.8M |
| Net Profit | — | $-1.2M |
| Gross Margin | 53.1% | 65.2% |
| Operating Margin | -13.4% | -37.2% |
| Net Margin | — | -25.5% |
| Revenue YoY | 2091.6% | 126.1% |
| Net Profit YoY | — | 70.5% |
| EPS (diluted) | $-0.05 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $6.1M | — | ||
| Q3 25 | $6.2M | — | ||
| Q2 25 | $5.7M | — | ||
| Q1 25 | $5.5M | — | ||
| Q4 24 | — | $4.8M | ||
| Q3 24 | — | $0 | ||
| Q2 24 | — | $2.4M | ||
| Q1 24 | — | $2.6M |
| Q4 25 | — | — | ||
| Q3 25 | $-1.1M | — | ||
| Q2 25 | $-1.1M | — | ||
| Q1 25 | $808.5K | — | ||
| Q4 24 | — | $-1.2M | ||
| Q3 24 | — | $-1.2M | ||
| Q2 24 | — | $-1.6M | ||
| Q1 24 | — | $-3.2M |
| Q4 25 | 53.1% | — | ||
| Q3 25 | 50.7% | — | ||
| Q2 25 | 50.1% | — | ||
| Q1 25 | 55.3% | — | ||
| Q4 24 | — | 65.2% | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 66.3% | ||
| Q1 24 | — | 68.2% |
| Q4 25 | -13.4% | — | ||
| Q3 25 | -23.0% | — | ||
| Q2 25 | -19.7% | — | ||
| Q1 25 | -24.2% | — | ||
| Q4 24 | — | -37.2% | ||
| Q3 24 | — | — | ||
| Q2 24 | — | -67.4% | ||
| Q1 24 | — | -87.1% |
| Q4 25 | — | — | ||
| Q3 25 | -17.4% | — | ||
| Q2 25 | -18.3% | — | ||
| Q1 25 | 14.7% | — | ||
| Q4 24 | — | -25.5% | ||
| Q3 24 | — | — | ||
| Q2 24 | — | -66.0% | ||
| Q1 24 | — | -122.2% |
| Q4 25 | $-0.05 | — | ||
| Q3 25 | $-0.08 | — | ||
| Q2 25 | $-0.08 | — | ||
| Q1 25 | $0.06 | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $-1.92 | ||
| Q2 24 | — | $-1.37 | ||
| Q1 24 | — | $-29.95 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $5.6M | $430.0K |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $18.2M | $-129.0K |
| Total Assets | $26.0M | $3.4M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $5.6M | — | ||
| Q3 25 | $7.3M | — | ||
| Q2 25 | $7.3M | — | ||
| Q1 25 | $9.7M | — | ||
| Q4 24 | — | $430.0K | ||
| Q3 24 | — | $776.0K | ||
| Q2 24 | — | $751.0K | ||
| Q1 24 | — | $1.8M |
| Q4 25 | $18.2M | — | ||
| Q3 25 | $18.8M | — | ||
| Q2 25 | $19.9M | — | ||
| Q1 25 | $21.1M | — | ||
| Q4 24 | — | $-129.0K | ||
| Q3 24 | — | $1.1M | ||
| Q2 24 | — | $-617.0K | ||
| Q1 24 | — | $160.0K |
| Q4 25 | $26.0M | — | ||
| Q3 25 | $27.2M | — | ||
| Q2 25 | $29.8M | — | ||
| Q1 25 | $31.1M | — | ||
| Q4 24 | — | $3.4M | ||
| Q3 24 | — | $3.9M | ||
| Q2 24 | — | $3.9M | ||
| Q1 24 | — | $5.4M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $87.6K | $-1.7M |
| Free Cash FlowOCF − Capex | — | $-1.7M |
| FCF MarginFCF / Revenue | — | -35.4% |
| Capex IntensityCapex / Revenue | — | 0.1% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $87.6K | — | ||
| Q3 25 | $133.0K | — | ||
| Q2 25 | $-888.7K | — | ||
| Q1 25 | $1.7M | — | ||
| Q4 24 | — | $-1.7M | ||
| Q3 24 | — | $-2.4M | ||
| Q2 24 | — | $-1.4M | ||
| Q1 24 | — | $-2.0M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $-1.7M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | $-2.0M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | -35.4% | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | -75.3% |
| Q4 25 | — | — | ||
| Q3 25 | 0.0% | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.1% | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 0.0% | ||
| Q1 24 | — | 0.1% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 2.16× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
IPM
| Procurement Revenue | $5.4M | 88% |
| Other | $743.9K | 12% |
NBY
| Other | $2.4M | 51% |
| Total Product Revenue | $2.3M | 49% |
